Milligan Sandra
Known title: DirectorCIK: 0001859810
Milligan Sandra's purchase track record
Milligan Sandra has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/19/2025 | GOSS | $50K | +58.9% | +12.0% | +6.7% |
| 11/15/2023 | GOSS | $25K | +19.2% | -8.5% | +17.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GOSS | ▲ Buy | Open Market | 26,050 | $50K | 8/19/2025 | View on chart |
| GOSS | ▲ Buy | Open Market | 32,000 | $25K | 11/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension
Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension. Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.